Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro

@article{Hwangbo2020AuranofinAN,
  title={Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro},
  author={Hyun Hwangbo and Min Yeong Kim and Seon Yeong Ji and So Young Kim and Hyesook Lee and Gi-Young Kim and Cheol Park and Young-Sam Keum and Su Hyun Hong and Jaehun Cheong and Yung-Hyun Choi},
  journal={Antioxidants},
  year={2020},
  volume={9}
}
Non-alcoholic fatty liver disease (NAFLD) causes liver dysfunction and is associated with obesity and type 2 diabetes. Chronic inflammation is associated not only with the development of NAFLD, but also with hepatic diseases, including steatohepatitis, cirrhosis, and hepatocellular carcinoma. Auranofin is a treatment for rheumatoid arthritis and has recently been reported to have potential effects against a variety of diseases, including inflammation, cancer, and viral infection. In this study… Expand

Figures from this paper

Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk
TLDR
While mitochondria DNA mutations and SNPs (single nucleotide polymorphisms) can be used as effective diagnostic markers and target for treatments, age and ethnic specificity should be taken into account. Expand
Effects of cytokine signaling inhibition on inflammation-driven tissue remodeling
Abstract Fibrosis is a common condition that can affect all body tissues, driven by unresolved tissue inflammation and resulting in tissue dysfunction and organ failure that could ultimately lead toExpand
Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe Streptococcus suis Infections
TLDR
Auranofin, an orally bioavailable FDA-approved anti-rheumatic drug, is identified as a candidate repurposed drug to treat severe S. suis infections and shows the potential for use as an effective antibiotic against S.suis infections. Expand
Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?
  • Muyun Wang, Kun Wang, +5 authors Qiang Li
  • Frontiers in Pharmacology
  • 2021
Lipid metabolism involves multiple biological processes. As one of the most important lipid metabolic pathways, fatty acid oxidation (FAO) and its key rate-limiting enzyme, the carnitineExpand

References

SHOWING 1-10 OF 61 REFERENCES
The Gut Microbiota and its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
TLDR
The current evidence regarding the key role of the gut microbiota and its metabolites in the pathogenesis and development of NAFLD is highlighted, and the advances in the progression and applied prospects of gut microbiota-targeted dietary and exercise therapies are discussed. Expand
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
TLDR
Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders. Expand
A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD
In 2018, there have been substantial advances in our understanding of the risk factors for advanced liver disease in nonalcoholic fatty liver disease, including genetic variants and the gutExpand
The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
TLDR
An overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH is provided. Expand
NAFLD: A critical role for the NLRP3 inflammasome in NASH
  • Hugh Thomas
  • Medicine
  • Nature Reviews Gastroenterology &Hepatology
  • 2017
TLDR
Results are the most powerful to date that indicate a key role for NLRP3 activation in the liver for NASH pathogenesis, according to new research published in the Journal of Hepatology. Expand
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
TLDR
A crucial role for the NLRP3 inflammasome gain of function leads to early and severe onset of diet-induced steatohepatitis in mice is uncovered and may lead to novel therapeutic strategies aimed at halting the progression of hepatic steatosis to the more severe forms of this disease. Expand
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
TLDR
It is shown that cholesterol crystals could be one pathway to activate the inflammasome in NASH, and a drug called MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. Expand
Caffeic acid ameliorates hepatic steatosis and reduces ER stress in high fat diet-induced obese mice by regulating autophagy.
TLDR
The results suggest that caffeic acid may ameliorate hepatic steatosis and decrease ER stress by increasing autophagy. Expand
Biomarkers in nonalcoholic fatty liver disease.
TLDR
The present review attempts to provide a comprehensive analysis of the emerging risk biomarkers of NAFLD and NASH, and to use the clinical significance and analytical considerations of each biomarker pointing out sentinel features of disease progression. Expand
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.
TLDR
Current evidence as it pertains to the epidemiology, pathogenesis, and prevention of NAFLD-associated HCC, including metformin and PPAR gamma agonists, is summarized. Expand
...
1
2
3
4
5
...